血清CYRFA21-1、proGRP、Periostin联合检测对非小细胞肺癌的诊断价值

Diagnostic value of serum CYRFA21-1,proGRP,Periostin combined assay in non-small cell lung cancer

目的研究血清细胞角蛋白19片段(CYRFA21-1)、胃泌素前体释放肽(proGRP)及骨膜蛋白(Periostin)联合检测对非小细胞肺癌(NSCLC)的诊断价值。方法回顾性选择2020年7月至2022年6月东莞市人民医院收治的NSCLC患者48例纳入NSCLC组,选取同期收治的肺部良性疾病患者48例纳入良性组,选取同期行体检的健康人48名纳入正常组。检测3组血清CYRFA21-1、proGRP、Periostin水平。观察3组血清CYRFA21-1、proGRP、Periostin水平;分析NSCLC组不同分期、是否淋巴结转移及病灶指标不同患者血清CYRFA21-1、proGRP、Periostin水平。分析CYRFA21-1、proGRP、Periostin与NSCLC临床资料及病理特征的相关性。结果NSCLC组血清CYRFA21-1、proGRP、Periostin水平均高于良性组、正常组,良性组以上指标均高于正常组,差异均有统计学意义(P<0.05)。NSCLC组Ⅲ期患者血清CYRFA21-1、proGRP、Periostin水平均高于I期、Ⅱ期患者,Ⅱ期患者以上指标均高于I期患者,差异均有统计学意义(P<0.05)。NSCLC组淋巴结转移患者血清CYRFA21-1、proGRP、Periostin水平均高于淋巴结未转移患者,差异均有统计学意义(P<0.05)。NSCLC组病灶直径≥3 cm患者血清CYRFA21-1、proGRP、Periostin水平均高于病灶直径<3 cm患者,差异均有统计学意义(P<0.05)。经Pearson相关分析,血清CYRFA21-1、proGRP、Periostin水平与NSCLC患者病灶大小、病灶分期及淋巴结转移呈正相关,与病灶分化程度呈负相关(P<0.05);与性别、年龄、病灶分型、病灶位置不相关(P>0.05)。结论血清CYRFA21-1、proGRP、Periostin联合诊断NSCLC具有较高的诊断价值。

Objective To study the diagnostic value of serum cytokeratin-19 fragment(CYRFA21-1),gastrin precursor releasing peptide(proGRP)and Periosteal protein(Periostin)combined assay in non-small cell lung cancer(NSCLC).Methods A total of 48 patients with NSCLC admitted to Dongguan People's Hospital from July 2020 to June 2022 were included in the NSCLC group,48 patients with pulmonary benign diseases treated during the same period were included in the benign group,and 48 healthy people who underwent physical examination during the same period were included in the normal group.Serum CYRFA21-1,proGRP and Periostin levels were determined in the three groups.Serum CYRFA21-1,proGRP and Periostin levels were observed in the three groups.Serum CYRFA21-1,proGRP and Periostin levels of patients in NSCLC group at different stages,lymph node metastasis or not,and focal indicators were analyzed.The correlation between CYRFA21-1,proGRP,Periostin and the clinical data and pathological features of NSCLC was analyzed.Results The serum CYRFA21-1,proGRP and Periostin levels in NSCLC group were higher than those in benign and normal groups,those of in benign group were higher than those in normal group,the differences were statistically significant(P<0.05).The serum CYRFA21-1,proGRP and Periostin levels in stageⅢpatients were higher than those in stage I and stageⅡpatients,those of in stageⅡpatients were higher than those in stage I patients,the differences were statistically significant(P<0.05).Serum CYRFA21-1,proGRP and Periostin levels in patients with lymph node metastasis in NSCLC group were higher than those in patients without lymph node metastasis,the differences were statistically significant(P<0.05).Serum CYRFA21-1,proGRP and Periostin levels in patients with lesion diameter≥3 cm in NSCLC group were higher than those in patients with lesion diameter<3 cm,the differences were statistically significant(P<0.05).According to Pearson correlation analysis,serum CYRFA21-1,proGRP and Periostin levels were positively correlated with lesion size,lesion staging and lymph node metastasis,and negatively correlated with lesion differentiation degree in NSCLC patients(P<0.05),there was no correlation with sex,age,focus type and location(P>0.05).Conclusion Serum CYRFA21-1,proGRP and Periostin combined is valuable in the diagnosis of NSCLC.